Now let me read the calibration papers referenced by the Human Finder reviewer:Now I have sufficient information. Let me compile the final review.

---

## Summary
GFMBench is a unified benchmarking and software platform for Genomic Foundation Models (GFMs), integrating four existing large-scale benchmarks (RGB, PGB, GUE, GB) covering 42 million genomic sequences across 75 datasets. The paper provides an automated evaluation pipeline (AutoBench), standardized model/tokenizer wrappers for heterogeneous GFM architectures, and an open-source genomics toolkit. A comprehensive evaluation of 10+ open-source GFMs is presented, with OmniGenome—which incorporates RNA structural context—consistently achieving top-tier performance, including on DNA tasks.

---

## Strengths

- **Practical benchmark aggregation**: Integrating RGB, PGB, GUE, and GB into a single automated framework is a genuine community service. No single prior tool covered all four suites, and the heterogeneity of GFM architectures (Transformer/Hyena/Mamba), tokenizers (k-mer/BPE/SNT), and evaluation protocols across these benchmarks makes unification non-trivial.

- **Standardization design is principled**: Freezing hyperparameters, mirroring metrics from scikit-learn, incorporating custom code hooks, and adopting FAIR metadata principles are sensible engineering choices. The paper correctly diagnoses a real pain point (inconsistent evaluation leading to irreproducible or biased comparisons, as evidenced by the E2EFold example in Sec. 1).

- **Heterogeneous architecture support**: The model and tokenizer wrapper templates that enable seamless benchmarking across Transformer, Hyena, and Mamba architectures is a genuine engineering contribution that lowers barriers for new model evaluation.

- **Cross-modal finding is scientifically interesting**: OmniGenome's RNA-pretrained model outperforming specialized DNA models on several PGB tasks (e.g., PolyA: 87.55 vs. RNA-FM's 84.94, Splice: 98.41 vs. SpliceBERT's 96.45) is a noteworthy empirical finding about cross-nucleic-acid-type transferability of structural pretraining.

- **Community infrastructure**: The public leaderboard, online hub, containerized environment, and contributed configurations provide durable community resources.

---

## Weaknesses

### Fatal
*(None that fully invalidate the paper, but see Major #1 and #3 below for issues that substantially weaken core claims.)*

### Major

1. **The results section validates models, not the framework** — The paper's stated contribution is a *benchmarking framework* (standardization, reproducibility, metric reliability, adaptive benchmarking). Yet Sec. 3 presents a model leaderboard and draws conclusions about OmniGenome's superiority and structural modeling benefits. The framework's own promises—that standardized protocols reduce inter-study variance, that AutoBench is more reproducible than prior tools, that adaptive benchmarking reveals cross-genomic patterns beyond ordinary multi-task evaluation—are never empirically validated. A benchmark paper should show *that the benchmark works as claimed*, not only *what results it produces*. For example, there is no comparison of GFMBench outputs against prior published baselines to confirm consistency, no demonstration that GFMBench resolves prior discrepancies (e.g., the E2EFold case motivating Sec. 1), and no test of the framework's sensitivity to implementation choices.

2. **Missing variance/error bars for three of four tables** — Table 1 (RGB) explicitly states results are "averaged based on five random seeds," but Tables 2 (PGB), 3 (GUE), and 4 (GB) carry no such statement and report single-point estimates with no standard deviations. Without variance, readers cannot determine whether margin differences between models (often small, e.g., OmniGenome 78.51 vs. SpliceBERT 77.66 on GUE Yeast EMP) are meaningful or noise. This is a core evaluation quality issue.

3. **PGB re-implementation without faithfulness validation** — The paper explicitly states (Sec. 2.1): *"Since the original evaluation protocol is not publicly available, we have re-implemented the auto-benchmark for all the subtasks from PGB in GFM Bench."* No evidence is provided that the reimplementation faithfully recovers the original protocol's intent. If the re-implementation diverges from the original in data splits, preprocessing, or metrics, all PGB model comparisons are against an undefined standard. This directly undermines the benchmarking standardization claim and weakens the PGB-based conclusions.

4. **Textual inconsistency in GUE results** — Section 3.3 states: *"For the Virus CVC task, OmniGenome also achieves the best performance with an F1 score of 74.72."* However, Table 3 clearly shows OmniGenome's Virus CVC score is **64.41**. This is a verified factual error in the narrative (not a parser artifact), indicating that the result discussion was not carefully proofread against the tables. Given that the paper's contribution relies on accurate reporting, this undermines confidence in result narration.

5. **Table 4 naming error** — The final row of Table 4 (GB) is labeled "GFMbench" rather than "OmniGenome," creating ambiguity about whether the benchmark framework itself is evaluated as a model. The surrounding text discusses "OmniGenome" results for the same table. This creates genuine confusion and suggests the final manuscript was not carefully verified.

6. **No direct comparison with existing benchmarking tools** — The paper names RNABench, GenBench, BEACON, and DEGB in related work but provides no feature-by-feature comparison or experimental demonstration of GFMBench's advantages over these alternatives. The claim that existing tools "do not prioritise the standardisation and automation of GFM benchmarking" is asserted but not demonstrated.

7. **"Adaptive benchmarking" is an engineering abstraction, not a validated protocol** — The paper introduces "adaptive benchmarking" as a key contribution (Sec. 1 and Sec. 2.1), but as implemented it means running diverse models across diverse benchmarks through a unified command without code modification. This is useful software design, but it is not a new benchmarking *methodology*. No experiment specifically exercises, validates, or shows the unique value of this "adaptive" dimension beyond what any unified multi-task evaluation already does.

### Minor

- **Causal overclaiming from observational rankings**: OmniGenome's superiority is repeatedly attributed to structural pretraining (e.g., *"This can be attributed to OmniGenome's integration of structural information"*). But the observed models differ in architecture, pretraining data size, tokenizer choice, and model scale simultaneously. No ablation isolates structural information as the causal factor. The attributions should be stated as hypotheses.

- **Missing non-GFM baselines**: The paper benchmarks only pretrained GFMs. Including simple baselines (CNNs, k-mer linear models, randomly initialized transformers) would contextualize whether GFM pretraining provides benefit at all on these tasks—a question already raised in the genomics community.

- **Pre-training data contamination not analyzed**: With 42M sequences from widely used databases, overlap between GFM pretraining corpora and benchmark test sets is plausible. The paper mentions sequence-identity filtering for structure prediction tasks specifically, but provides no contamination analysis for the remaining tasks.

### Trivial

- The paper's framing oscillates between "benchmarking framework" and "genomics application software" (RNA design, augmentation, etc.). While both are described, their co-contribution is not clearly motivated.

---

## Nice-to-Haves

- Add ablation comparing frozen vs. per-model-tuned hyperparameters to validate that standardized settings are indeed fair across heterogeneous architectures.
- Provide a feature comparison table (GFMBench vs. GenBench, BEACON, DGEB, DEGB) on dimensions such as automation, task diversity, model coverage, and standardization depth.
- Add visualization (heatmap or radar chart) of per-model per-task performance to reveal systematic patterns across architecture types.
- Provide computational cost reporting (GPU-hours, memory) so users can assess feasibility.
- Investigate structural vs. non-structural ablations within OmniGenome to strengthen causal claims about pretraining.
- Include a short worked example / case study showing a new user benchmarking a custom GFM end-to-end.

---

## Removed Points

*These points are flagged for removal; treat with caution — they reflect reviewer misreadings or unsupported concerns:*

- **Harsh Critic — Frozen hyperparameters as systematically unfair**: The critic argues frozen hyperparameters could bias comparisons against certain architectures. While this is a real tradeoff, the paper explicitly acknowledges it as a deliberate reproducibility choice. The tradeoff between per-model fairness and cross-study reproducibility is a known tension in benchmarking methodology; choosing reproducibility is reasonable and within the scope of a benchmark paper. This is weakened to a nice-to-have (ablation).

- **Harsh Critic — Reproducibility claims need cross-machine reruns**: Demanding cross-machine reruns, sensitivity analyses across all seeds for all tables, or formal proof of reproducibility infrastructure exceeds the standard expected in benchmarking papers. Seeded results, public code, and configuration distribution are the norm. This concern is absorbed into the verified variance criticism (missing error bars for Tables 2-4).

- **Human Finder — Missing baseline comparisons with non-pretrained models (CNNs, etc.)**: While useful context, a GFM-specific benchmarking paper is not obligated to include non-GFM baselines as a core contribution. This is weakened to a minor point.

---

## Novel Insights

The most novel empirical observation is the cross-modal RNA→DNA generalization: OmniGenome, pretrained exclusively on RNA with structural context, outperforms specialized DNA models on several plant genomic tasks (PGB) and achieves competitive performance on human/virus genomic tasks (GUE). This suggests that structural pretraining may encode transferable nucleic acid representations beyond modality boundaries—a finding with non-obvious implications for GFM design. However, the paper currently treats this as a descriptive observation rather than a controlled experiment, and it requires ablation before causal attribution is warranted.

---

## Suggestions

1. **Fix GUE Virus CVC inconsistency**: Reconcile the 74.72 stated in the text with 64.41 in Table 3. Verify all numerical claims in Section 3 against their source tables.
2. **Fix Table 4 row label**: Change "GFMbench" to "OmniGenome" (or clarify what "GFMbench" means in this context).
3. **Add error bars to Tables 2–4**: Report mean ± std across at least 3 random seeds, consistent with Table 1.
4. **Validate PGB reimplementation**: Compare at least one model's PGB results against any available external report, or provide a methodological argument for why the reimplementation is conservative/unbiased.
5. **Demonstrate framework value empirically**: Show one concrete example where GFMBench resolves a discrepancy documented in prior work (e.g., the E2EFold case), or compare GFMBench-produced numbers for a model against the model's originally reported numbers.
6. **Sharpen "adaptive benchmarking" contribution**: Either provide a concrete definition of what constitutes an adaptive benchmark setting (input criteria, evaluation protocol), or reframe it as "seamless cross-suite evaluation" without claiming it as a protocol innovation.

---

## Score and Decision

**Calibration:**

- **GeneBench (0bswm093Yl)**: A very similar paper — GFM benchmarking framework with multi-task evaluation. Scores 5, 6, 3, 5 (avg ~4.75); Withdrawn. GeneBench additionally proposed a new hybrid model (GenHybrid), giving it more novelty than GFMBench, yet was rejected.
- **COMET (C81bqFCmMf)**: Multi-omics benchmark with broader scope, scores 5, 5, 5, 8 (avg ~5.75); Rejected. Had similar issues with metric inconsistency and overclaiming.
- **DGEB (fopjVghcE2)**: More novel benchmark design with new datasets, scores 6, 5, 5, 6 (avg ~5.5); Rejected. Had stronger methodological contributions (sequence-identity-controlled splits).
- **GDDqq0w6rs**: Scores 5, 5, 3, 6 (avg ~4.75); Rejected. Similar diagnosis of limited novelty.

GFMBench sits below DGEB in novelty (all benchmarks are existing; no new evaluation methodology beyond standard aggregation) and below GeneBench in experimental contribution (no new model). The verified errors (GUE textual inconsistency, Table 4 mislabeling), the absent variance for 3/4 tables, the PGB reimplementation without validation, and the non-validated "adaptive benchmarking" claim collectively make this a weaker execution than any of the calibration papers above. The practical software contribution and benchmark aggregation are real, but insufficient given the calibration anchors.

**Score: 4.0**

The paper identifies a genuine need and provides useful engineering infrastructure, but the empirical validation of the framework's core promises is missing, the results contain verified errors, and the novelty relative to existing benchmarking tools is asserted rather than demonstrated. In line with calibration papers of similar or greater contribution that were rejected (3–6 range), this paper falls at the low end.

MY FINAL SCORE: <pineapple>4.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>